AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 26 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - University of Iowa researchers have developed recombinant therapies that can treat and prevent prostate cancer tumors in mice.
According to a contingent of investigators at the Iowa City, Iowa university, "Prostatic malignancies in 95% of patients continue to express PSA, making this antigen a good candidate for targeted immunotherapy." Because the cells in the prostrate are significant producers of PSA, they are key targets for directed therapies such as that developed by Bennett D. Elzey and others at University of Iowa.
The first portion of the therapy, an adenovirus construct, expresses recombinant prostate-specific antigen (PSA) while the second part of the therapy consists of viruses encoded for several cytokines. Together, the two constructs reduced tumor size and inhibited the formation of new tumors upon cancer cell rechallenge in murine models of prostate cancer.
"Immunization of mice with recombinant PSA adenovirus type 5 (Ad5-PSA) induced PSA-specific cellular and humoral immunity that was protective against a subcutaneous challenge with RM11 prostate cancer cells expressing PSA (RM11psa), but not mock-transfected RM11 tumor cells (RM11neo)," Elzey and coworkers said. The growth of existing tumors was not affected by adenoviral transfer of PSA.
Mice vaccinated with a control vector did not develop a similar protective immune response against prostate cancer cells, research team members maintained.
"Antitumor activity was predominantly mediated by CD8[superscript]+ T lymphocytes," they pointed out.
...
Source: HighBeam Research, Antigen Construct, Cytokine Combo Treats and Prevents Male...